Sage Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Sage Therapeutics has a total shareholder equity of $551.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $622.4M and $70.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$569.15m |
| Equity | US$551.84m |
| Total liabilities | US$70.60m |
| Total assets | US$622.43m |
Recent financial health updates
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Recent updates
CNS Drug Development: Same As It Ever Was
Nov 19Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Oct 07Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Aug 30Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Jul 25Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
Jul 13Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05Financial Position Analysis
Short Term Liabilities: SAGE's short term assets ($605.0M) exceed its short term liabilities ($60.4M).
Long Term Liabilities: SAGE's short term assets ($605.0M) exceed its long term liabilities ($10.2M).
Debt to Equity History and Analysis
Debt Level: SAGE is debt free.
Reducing Debt: SAGE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SAGE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SAGE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 6.5% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 04:51 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sage Therapeutics, Inc. is covered by 39 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Esther Lannie Hong | Berenberg |
| null null | BMO Capital Markets Equity Research |